Stability indicating reversed-phase high-performance liquid chromatographic and thin layer densitometric methods for the determination of ziprasidone in bulk powder and in pharmaceutical formulations

被引:37
作者
El-Sherif, ZA
El-Zeany, B
El-Houssini, OM
Rashed, MS
Aboul-Enein, HY
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Pharmaceut Anal Lab, Riyadh 11211, Saudi Arabia
[2] Natl Org Drug Control & Res, Cairo, Egypt
[3] Cairo Univ, Fac Pharm, Dept Analyt Chem, Cairo 11562, Egypt
[4] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Metabol Screening Lab, Riyadh 11211, Saudi Arabia
关键词
ziprasidone; antipsychotic drug; pharmaceutical capsules; bulk materials; purity evaluation; degradation products;
D O I
10.1002/bmc.299
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Two sensitive and reproducible methods were developed and validated for the determination of ziprasidone (ZIP) in the presence of its degradation products in pure form and in pharmaceutical formulations. The first method was based on reversed-phase high-performance liquid chromatography (HPLC), on a Lichrosorb RP C, column using water:acetonitrile:phosphoric acid (76:24:0.5 v/v/v) as the mobile phase at a flow rate of 1.5 mL min(-1) at ambient temperature. Quantification was achieved with UV detection at 229 run over a concentration range of 10-500 mug mL(-1) with mean percentage recovery of 99.71 +/- 0.55. The method retained its accuracy in presence of up to 90% of ZIP degradation products. The second method was based on TLC separation of ZIP from its degradation products followed by densitometric measurement of the intact drug spot at 247 nm. The separation was carried out on aluminium sheet of silica gel 60 F,, using choloroform:methanol:glacial acetic acid (75:5:4.5 v/v/v) as the mobile phase, over a concentration range of 1-10 mug per spot and mean percentage recovery of 99.26 +/- 0.39. Both methods were applied successfully to laboratory prepared mixtures and pharmaceutical capsules. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 10 条
[1]  
CLAY CF, 2002, ANN PHARMACOTHER, V36, P839
[2]   Stability indicating methods for the determination of loratadine in the presence of its degradation product [J].
El Ragehy, NA ;
Badawey, AM ;
El Khateeb, SZ .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1041-1053
[3]   Spotlight on ziprasidone in schizophrenia and schizoaffective disorder [J].
Gunasekara, NS ;
Spencer, CM ;
Keating, GM .
CNS DRUGS, 2002, 16 (09) :645-652
[4]   Ziprasidone - A review of its use in schizophrenia and schizoaffective disorder [J].
Gunasekara, NS ;
Spencer, CM ;
Keating, GM .
DRUGS, 2002, 62 (08) :1217-1251
[5]   Stability indicating methods for the determination of diloxanide furoate [J].
Hasan, NY ;
Elkawy, MA ;
Elzeany, BE ;
Wagieh, NE .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (02) :187-197
[6]  
ICH, 2003, STAB TEST NEW DRUG S
[7]   DEVELOPMENT AND VALIDATION OF A HIGH-SENSITIVITY ASSAY FOR AN ANTIPSYCHOTIC AGENT, CP-88,059, WITH SOLID-PHASE EXTRACTION AND NARROW-BORE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
JANISZEWSKI, JS ;
FOUDA, HG ;
COLE, RO .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01) :133-139
[8]  
JANISZEWSKI JS, 1998, RAPID COMMUNICATIONS, V11, P1033
[9]   Determination and degradation study of haloperidol by high performance liquid chromatography [J].
Trabelsi, H ;
Bouabdallah, S ;
Bouzouita, K ;
Safta, F .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (04) :649-657
[10]   Determination of bronopol and its degradation products by HPLC [J].
Wang, HF ;
Provan, GJ ;
Helliwell, K .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (1-2) :387-392